Perceptions of methotrexate use in rheumatoid arthritis by rheumatologists and their patients: an Australian survey study. (1st November 2013)

• Record Type: Journal Article
• Authors: Nash, Peter; Nicholls, Dave
• Is Part Of: International journal of rheumatic diseases. Volume 16:Number 6(2013)
• Page Start: 652
• Page End: 661
• Publication Date: 2013-11-01
• Subjects: arthritis rheumatoid -- methotrexate -- patient preferences -- survey health; Rheumatology -- Periodicals; Rheumatology -- Asia -- Periodicals; Rheumatology -- Pacific Area -- Periodicals; Rheumatic Diseases -- Periodicals; Connective Tissue Diseases -- Periodicals; Immune System Diseases -- Periodicals; 616.723
• DOI: 10.1111/1756-185X.12183
• Languages: English
• ISSNs: 1756-1841

Abstract

Abstract: Aim: To improve treatment for rheumatoid arthritis (RA), rheumatologists have embraced patient‐reported outcomes; however, limited data are available on patient perceptions of treatment. Our objective was to assess the use and perceptions of methotrexate (MTX) by patients with RA (primary objective) and their rheumatologists, patient‐reported adverse events (AEs) related to MTX, and patient‐reported use of alcohol, folic acid and biologic agents. Method: Each rheumatologist completed a rheumatologist questionnaire and then asked patients with RA to complete a patient questionnaire. Results: Questionnaires were completed by 46/50 rheumatologists and 1313/1313 patients. Patients (72% female, 38% > 10 years RA) took oral MTX regularly (72% never miss a dose) and at therapeutic doses. Most patients (79%) were currently taking MTX, but 36% of patients were on low doses (≤ 10 mg/week) and 8% intentionally and regularly did not take MTX. Most patients had a positive perception of MTX; 82% of patients considered MTX to be important; 60% preferred to continue taking MTX. Although AEs (generally mild and gastrointestinal) occurred regularly (38%) and in some patients continuously (13%), 41% of patients did not experience an AE. Patients abstained from alcohol (46%) and took folic acid (91%, but with variable dosage regimens and doses). There were 29% of patients taking biologic agent therapy; only 70% of these patients were also taking MTX. Conclusion: MTX was well used, well tolerated and well perceived. However, to ensure that MTX therapy is as effective as possible, rheumatologists should discuss MTX use with their patients and consider alternative strategies for some patients.